GSK (GSK)

Sector:

Pharma and Biotech

Index:

FTSE 100

 1,395.50p
   
  • Change Today:
      0.000p
  • 52 Week High: 1,671.00p
  • 52 Week Low: 1,264.00p
  • Currency: UK Pounds
  • Shares Issued: 4,087.27m
  • Volume: 0
  • Market Cap: £57,038m
  • RiskGrade: 129

Latest ShareCast News

EMA accepts marketing authorisation application for GSK's linerixibat

By Josh White

Date: Monday 23 Jun 2025

(Sharecast News) - GSK said on Monday that the European Medicines Agency has accepted its marketing authorisation application for linerixibat, an investigational treatment for cholestatic pruritus in patients with primary biliary cholangitis (PBC).

GSK hoping to expand Arexvy usage in Japan

By Benjamin Chiou

Date: Friday 20 Jun 2025

(Sharecast News) - Japanese regulators have accepted GSK's application to expand the use of its RSV vaccine, Arexvy, to the entire adult population.

GSK's RSV vaccine accepted for regulatory review by EMA

By Iain Gilbert

Date: Friday 13 Jun 2025

(Sharecast News) - Drugmaker GSK said on Friday that its RSV vaccine, Arexvy, has been accepted for regulatory review by the European Medicines Agency to expand use in adults 18 years and older.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

GSK Market Data

Currency UK Pounds
Share Price 1,395.50p
Change Today 0.000p
% Change 0.00 %
52 Week High 1,671.00p
52 Week Low 1,264.00p
Volume 0
Shares Issued 4,087.27m
Market Cap £57,038m
RiskGrade 129

GSK Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
46.9% below the market average46.9% below the market average46.9% below the market average46.9% below the market average46.9% below the market average
39.13% above the sector average39.13% above the sector average39.13% above the sector average39.13% above the sector average39.13% above the sector average
Price Trend
5.16% above the market average5.16% above the market average5.16% above the market average5.16% above the market average5.16% above the market average
43.48% above the sector average43.48% above the sector average43.48% above the sector average43.48% above the sector average43.48% above the sector average
Income
74.93% above the market average74.93% above the market average74.93% above the market average74.93% above the market average74.93% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Growth
32.23% below the market average32.23% below the market average32.23% below the market average32.23% below the market average32.23% below the market average
62.5% below the sector average62.5% below the sector average62.5% below the sector average62.5% below the sector average62.5% below the sector average

What The Brokers Say

Strong Buy 3
Buy 2
Neutral 16
Sell 3
Strong Sell 0
Total 24
neutral
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

GSK Dividends

  Latest Previous
  Q1 Q4
Ex-Div 15-May-25 20-Feb-25
Paid 10-Jul-25 10-Apr-25
Amount 16.00p 16.00p

Trades for --2025

Time Volume / Share Price
0 @ 0.000p

GSK Key Personnel

CEO Emma Walmsley

Top of Page